BIOLOGICAL · Unmapped registry intervention
EB-DART-NK01
Find medicine records ·
Find other trials using this name
Clinical trial
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
NCT07744256
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Lymphodepleting chemotherapy
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Small Cell Lung Cancer (SCLC)unresolved
Relapsed/Refractory SCLCunresolved
Extensive-stage SCLCunresolved
Interventions
EB-DART-NK01BIOLOGICAL
Sponsors & collaborators
Beijing Biotechlead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07744256 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.